Announced Sat, 18 Jul · 16:39 IST
Natco gets tentative US FDA nod for Olaparib tablets
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.7%1-day move
₹944.75
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+1.7-1.4-2.4-2.3-1.9—————
Up moveDown movePending
AI summary
Natco Pharma has received tentative approval from the US FDA for Olaparib tablets (100 mg and 150 mg), a generic version of AstraZeneca's Lynparza used in cancer treatment. Natco will manufacture the drug while partner Alembic Pharmaceuticals will distribute it in the US. Olaparib had estimated US sales of about USD 1.4 billion in the 12 months ending March 2026. Para IV patent litigation is still ongoing, so commercial launch depends on its outcome.
Likely market impact
Positive for US revenue potential once patent litigation resolves; not immediately revenue-generating as launch awaits litigation outcome.